Pubmed    Pubmed Central
uBio Home | uBioRSS

WebSearchLiteratureMolecularImages

 uBio  Web Results 1 - 10 of about 73

Synonyms:
   Hylorchilus navai (Nava's Wren) 

Broader Terms:
   Hylorchilus 
   Passeriformes (Songbirds) 
   Troglodytidae (wrens) 
 
 
Latest Articles on Hylorchilus navai from uBioRSS
RangeĖdiversity plots for conservation assessments: Using richness and rari... - ScienceDirect Publication: Biological Conservation
Prioritisation of Mexican lowland rain forests for conservation using model... - ScienceDirect Publication: Journal for Nature Cons...


External Resources:

Common Names: Chivir√≠n de Nava, Chivir√ɬ≠n de Nava, Nava's Wren, Chivir√Ćn de Nava



1.  Severe COVID-19 infection in a child receiving immunotherapy for cancer.LinkIT
Smith VR, Whittle SB, Coleman RD, Munoz FM, De Guzman MM, Foster JH, Navai SA
Pediatric blood & cancer, 2021
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0

2.  Oncologic equipoise between robotic and open radical cystectomy.LinkIT
Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N
Journal of endourology, 2021
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0

3.  Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.LinkIT
Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM
The Journal of urology, 2021
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0

4.  Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.LinkIT
Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CPN, Kamat AM
BJU international BJU Int Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. 10.1111/bju.15344 To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin (BCG) response and progression in patients with non-muscle-invasive bladder cancer (NMIBC). We performed an institutional review board-approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US Food and Drug Administration, at our institution between 2000 and 2018. Patients were stratified by presence of any UTUC and time of UTUC diagnosis (preceding vs synchronous to NMIBC diagnosis or metachronous disease after NMIBC diagnosis). Descriptive statistics were used to summarize the data overall and by groups, and t-tests or Wilcoxon's rank sum tests and Pearson's chi-squared or Fisher's exact tests were used to analyse continuous and categorical data, respectively. Of 541 patients with NMIBC treated with adequate BCG, 59 (10.9 %) were diagnosed with UTUC. Of these, 34 had a history of UTUC prior to NMIBC (UTUC-P; median [interquartile range {IQR}] 13.1¬†[7.4-27.6]¬†months prior), while 25 developed UTUC after diagnosis of NMIBC (six synchronous and 19 metachronous; median [IQR] 12.1 [1.7-28.1]¬†months after). Compared to the non-UTUC group, patients with UTUC-P were more likely to exhibit Tis without papillary tumour in the bladder (20.6% vs 5.0%; P < 0.001), but were less likely to have T1 disease on index transurethral resection (8.8% vs 49.4%; P < 0.001). Patients with UTUC-P developed more recurrences (55.9% vs 34.0%; P = 0.010), any stage/grade progression (23.5% vs 9.8%; P = 0.012) and progression to muscle-invasive or metastatic disease (17.6% vs 6.4%; P = 0.014). The presence of high-grade UTUC-P compared to low-grade UTUC-P was associated with increased NMIBC recurrence (68.2% vs 25.0%; P = 0.049). There was no significant difference in rates of recurrence or progression based on timing of UTUC with respect to the index bladder tumour, although this analysis was limited by small numbers. Presence of UTUC prior to a diagnosis of NMIBC was associated with an almost twofold increased recurrence and progression rates after adequate BCG therapy. This should be considered when counselling patients and designing cohorts for clinical trials. ¬© 2021 The Authors BJU International ¬© 2021 BJU International. Bree Kelly K KK https://orcid.org/0000-0003-4532-7763 Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hensley Patrick J PJ Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Brooks Nathan A NA https://orcid.org/0000-0002-5111-6914 Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Matulay Justin J Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Li Roger R https://orcid.org/0000-0003-1274-7200 Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. Nogueras Gonzalez Graciela M GM Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Navai Neema N Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Grossman Herbert Barton HB Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Matin Surena F SF https://orcid.org/0000-0003-1638-1445 Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Dinney Colin P N CPN Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Kamat Ashish M AM Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. eng Wayne B. Duddlesten Professorship in Cancer Research P50CA091846 NIH/NCI UTMD Anderson SPORE in Genitourinary Cancer (Bladder) NCI Grant P30 CA016672 Cancer Center Support Grant Raymond and Maria Floyd Bladder Cancer Research Foundation Grant Journal Article 2021 01 22 England BJU Int 100886721 1464-4096 IM #BladderCancer #blcsm #uroonc #utuc To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin bacillus Calmette-Guerin bladder cancer intravesical BCG non-muscle-invasive bladder cancer upper tract urothelial carcinoma 2021 1 24 6 0 2021 1 24 6 0 2021 1 23 5 43 aheadofprint 33484074 10.1111/bju.15344 References, 2021</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br>5.  <a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 class=title>CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.</a><a href=http://ubio.org/tools/linkit.php?map%5B%5D=all&link_type=2&url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0><img src=linkit.png border=0 title='LinkIT' alt='LinkIT'></a> <br><span class=j>Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, Morris JS, Luong A, Mart√≠nez-Paniagua MA, Sanber K, Navai SA, Gad AZ, Salsman VS, Mathew PR, Kim HN, Wagner DL, Brunetti L, Jang A, Baker ML, Varadarajan N, Hegde M, Kim YM, Heisterkamp N, Abdel-Azim H, Ahmed N<br><font color=gray><i>Leukemia, 2021</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br>6.  <a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 class=title>Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers.</a><a href=http://ubio.org/tools/linkit.php?map%5B%5D=all&link_type=2&url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0><img src=linkit.png border=0 title='LinkIT' alt='LinkIT'></a> <br><span class=j>Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N<br><font color=gray><i>Urologic oncology, 2020</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br>7.  <a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 class=title>Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.</a><a href=http://ubio.org/tools/linkit.php?map%5B%5D=all&link_type=2&url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0><img src=linkit.png border=0 title='LinkIT' alt='LinkIT'></a> <br><span class=j>Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P<br><font color=gray><i>Nature medicine, 2020</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br>8.  <a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 class=title>The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu√©rin.</a><a href=http://ubio.org/tools/linkit.php?map%5B%5D=all&link_type=2&url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0><img src=linkit.png border=0 title='LinkIT' alt='LinkIT'></a> <br><span class=j>Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM<br><font color=gray><i>BJU international BJU Int The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu√©rin. 10.1111/bju.15296 To evaluate if the obesity paradox, wherein obesity portends worse overall prognosis for a disease but improved outcomes for patients receiving immunotherapy, exists for patients receiving bacillus Calmette-Gu√©rin (BCG) in a contemporary cohort. We performed an Institutional Review Board-approved database review to identify patients with non-muscle-invasive bladder cancer (NMIBC) completing at least an induction course of BCG. Clinicopathological variables collected included: body mass index (BMI), medications, and diabetes mellitus (DM). Outcomes of interest included: recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Univariate and multivariate modelling were used to evaluate the association between outcomes and clinical factors. A total of 579 patients (median follow-up 4.6¬†years) received BCG induction for NMIBC; 90% had high-grade disease (47.2% clinical stage T1). In all, 75.7% of patients were overweight or obese and 18% had DM. Aspirin, statins, metformin and ?-blockers were used in 34%, 42%, 11%, and 29% of patients, respectively. Overweight and obese patients had improved PFS, CSS and OS. DM was associated with worse RFS. Medications of interest had no association with outcomes. Elevated BMI is associated with improved outcomes in patients with NMIBC treated with BCG immunotherapy. Patients with DM are at increased risk of recurrence. These findings support a potential obesity paradox in bladder cancer. Evaluation of the underlying mechanism and the role of global patient assessment, counselling, and risk factor modification are warranted. ¬© 2020 The Authors BJU International ¬© 2020 BJU International Published by John Wiley & Sons Ltd. Brooks Nathan A NA https://orcid.org/0000-0002-5111-6914 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Kokorovic Andrea A https://orcid.org/0000-0002-1957-7999 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Xiao Lianchen L Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Matulay Justin T JT https://orcid.org/0000-0002-2467-5710 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Li Roger R https://orcid.org/0000-0003-1274-7200 Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. Ranasinghe Weranja K B WKB Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Nagaraju Supriya S Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Shen Yu Y Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Gao Jianjun J Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Navai Neema N Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Dinney Colin P N CPN Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Grossman H Barton HB Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Kamat Ashish M AM Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eng P60Ca091846 Foundation for the National Institutes of Health Wayne B. Duddlesten Professorship Maria Floyd Research Award Journal Article 2020 11 14 England BJU Int 100886721 1464-4096 IM #Bladder Cancer #blcsm #uroonc Bacillus Calmette-Gu√©rin body mass index diabetes mellitus non-muscle-invasive bladder cancer obesity paradox 2020 11 20 6 0 2020 11 20 6 0 2020 11 19 5 56 aheadofprint 33210440 10.1111/bju.15296 References, 2020</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br>9.  <a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 class=title>Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis.</a><a href=http://ubio.org/tools/linkit.php?map%5B%5D=all&link_type=2&url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0><img src=linkit.png border=0 title='LinkIT' alt='LinkIT'></a> <br><span class=j>Westerman ME, Kokorovic A, Wang XS, Lim A, Garcia-Gonzalez A, Seif M, Wang R, Kamat AM, Dinney CPN, Navai N<br><font color=gray><i>The journal of sexual medicine, 2020</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br>10.  <a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 class=title>Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.</a><a href=http://ubio.org/tools/linkit.php?map%5B%5D=all&link_type=2&url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0><img src=linkit.png border=0 title='LinkIT' alt='LinkIT'></a> <br><span class=j>Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N<br><font color=gray><i>Nature communications, 2020</i></font><br><font color=#008000>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0<br></font></span><br><br><br><table cellspacing=0 cellpadding=0 align=center><tr valign=bottom><td align=center><img src=p.png border=0></td><td align=center><img src=o_red.png border=0></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=2><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=3><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=4><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=5><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=6><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=7><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=8><img src=o_yellow.png border=0></a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=2><img src=rtal.png border=0></a></td></tr><td align=center></td><td align=center>1</td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=2>2</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=3>3</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=4>4</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=5>5</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=6>6</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=7>7</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=8>8</a></td><td align=center><a href=http://ubio.org/portal/index.php?search=Hylorchilus+navai&category=l&client=pubmed&startPage=2>¬Ľ</a></td></tr></table></table></tr></table></td><script src="http://www.google-analytics.com/urchin.js" type="text/javascript"> </script> <script type="text/javascript"> _uacct = "UA-634822-1"; urchinTracker(); </script> </BODY> </HTML>